Jan 10, 2022 / 03:30PM GMT
Jessica Macomber Fye - JPMorgan Chase & Co, Research Division - Analyst
Good morning, everyone. My name is Jess Fye. I'm a senior biotech analyst at JPMorgan, and we're continuing the 40th Annual Healthcare Conference today with Halozyme. I'm joined by the company's CEO, Dr. Helen Torley, who is going to give a presentation, and then we're going to go into Q&A after that. If you want to ask a question, there's a blue, ask a question button on your screen. Enter it, and then it'll send it to me, and I can ask management during the Q&A session. So with that, let me turn it over to Helen.
Helen I. Torley - Halozyme Therapeutics, Inc. - President, CEO & Director
Thanks, Jess, and I'm delighted to be here to provide an update on the Halozyme growth story. This presentation is also available on the Halozyme website.
I'll begin on Slide 2. In the course of all of my presentation, I will be making forward-looking statements, and I refer you to our SEC filings for a full listing of the risks and uncertainties.
And moving now to Slide 3.
Halozyme Therapeutics Inc at JPMorgan Healthcare Conference (Virtual) Transcript
Feb 07, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers